Ultra high affinity neutralizing antibodies
Ultra high affinity antibodies with binding affinities in the range of 10 10 M -1 , and even 10 11 M -1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either hu...
Saved in:
Main Authors | , , , , , |
---|---|
Format | Patent |
Language | English |
Published |
15.04.2010
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Ultra high affinity antibodies with binding affinities in the range of 10 10 M -1 , and even 10 11 M -1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and/or treat disease, especially virus-induced diseases, are also disclosed. |
---|---|
AbstractList | Ultra high affinity antibodies with binding affinities in the range of 10 10 M -1 , and even 10 11 M -1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and/or treat disease, especially virus-induced diseases, are also disclosed. |
Author | LESLIE S. JOHNSON HERREN WU JAMES F. YOUNG JEFFRY D. WATKINS WILLIAM D. HUSE SCOTT KOENIG |
Author_xml | – fullname: SCOTT KOENIG – fullname: JEFFRY D. WATKINS – fullname: HERREN WU – fullname: JAMES F. YOUNG – fullname: LESLIE S. JOHNSON – fullname: WILLIAM D. HUSE |
BookMark | eNrjYmDJy89L5WTQDs0pKUpUyMhMz1BITEvLzMssqVTISy0FCuZkVmXmpSsk5pVkJuWnZKYW8zCwpiXmFKfyQmluBmU31xBnD93Ugvz41OKCxOTUvNSSeMdQIwNDAxC2NHA0NCZOFQAfuSw- |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
ExternalDocumentID | AU2010201090A1 |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_AU2010201090A13 |
IEDL.DBID | EVB |
IngestDate | Fri Jul 19 14:02:15 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_AU2010201090A13 |
Notes | Application Number: AU20100201090 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20100415&DB=EPODOC&CC=AU&NR=2010201090A1 |
ParticipantIDs | epo_espacenet_AU2010201090A1 |
PublicationCentury | 2000 |
PublicationDate | 20100415 |
PublicationDateYYYYMMDD | 2010-04-15 |
PublicationDate_xml | – month: 04 year: 2010 text: 20100415 day: 15 |
PublicationDecade | 2010 |
PublicationYear | 2010 |
RelatedCompanies | MEDIMMUNE, LLC |
RelatedCompanies_xml | – name: MEDIMMUNE, LLC |
Score | 2.7727203 |
Snippet | Ultra high affinity antibodies with binding affinities in the range of 10 10 M -1 , and even 10 11 M -1 are disclosed. Such antibodies include antibodies... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | BEER BIOCHEMISTRY CHEMISTRY ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
Title | Ultra high affinity neutralizing antibodies |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20100415&DB=EPODOC&locale=&CC=AU&NR=2010201090A1 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQSUtMtDA1MjfQNbI0NNI1STNN000ENsR1E5MMjROBHQCLNPDtDb5-Zh6hJl4RphFMDDmwvTDgc0LLwYcjAnNUMjC_l4DL6wLEIJYLeG1lsX5SJlAo394txNZFDdo7Bh1_Zmiq5uJk6xrg7-LvrObsDOxJqvkFgeWMwKsQHYF9JVZQQxp00r5rmBNoX0oBcqXiJsjAFgA0L69EiIEpNU-YgdMZdveaMAOHL3TKG8iE5r5iEQbt0JySokQF0AnDColpaZnA3FipkJdaCh6sqALWQQrAYMpMygctDBRlUHZzDXH20AXaGg_3ZLxjKLITjcUYWIDd_1QJBgXjJKPkJEuzFGPjRFMTYwPLRLNUk9SkNJPUFENgr9jYUpJBBp9JUvilpRm4IPPhJrqGpjIMLCVFpamywGq2JEkOHDoA3Ch_yw |
link.rule.ids | 230,309,786,891,25594,76903 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT8IwEL8QNOKbokYUdYlmL2aRrRuwB2JgY5nKBjGb4Y200CZLyCAwYvSv91aH8sRb0ybX9pLr9XefAA-C0rZltBqaYeuGZgpLaBQ_4hplOqEIANpCdm8IwqYfm69ja1yC-TYXRtYJ_ZTFEVGipijvmXyvl_9GLFfGVq6fWIJTi2cv6rhqgY7z8me6pbq9Tn80dIeO6jiIJNXwXa4ZMgqxi1jpoIWgUIKlj16el7LcVSreCRyOkF6anUKJp1WoONvea1U4CgqXNw4L6VufwWM8z1ZUySsMK1SIBKXxS0n5RhorvlEHKcimhC3ywMBzuPf6keNruOvk75KTbrx7RHIBZYT__BIUwowps5szQqhlkoZNm9zkTJh8piMqJnYN6vsoXe1fvoOKHwWDyeAlfLuG41_fuKnpVh3K2WrDb1DlZuxWcuoH-waCtQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Ultra+high+affinity+neutralizing+antibodies&rft.inventor=SCOTT+KOENIG&rft.inventor=JEFFRY+D.+WATKINS&rft.inventor=HERREN+WU&rft.inventor=JAMES+F.+YOUNG&rft.inventor=LESLIE+S.+JOHNSON&rft.inventor=WILLIAM+D.+HUSE&rft.date=2010-04-15&rft.externalDBID=A1&rft.externalDocID=AU2010201090A1 |